Coming from an immunology background, Professor Greenman is extremely interested in understanding how the immune system is often subverted during carcinogenesis, and more importantly how such knowledge can be used clinically (diagnostically, prognostically or therapeutically).
Current and recent grants
H2020-MSCA-RISE-2016, €976,000 (€153k to Hull) (Greenman). Blood test for clinical therapy guidance of non-small cell lung cancer patients.
Yorkshire Cancer Research, €99,198 (Lind and Greenman). Peripheral blood detection of EGFR status in lung cancer patients. 01/11/2016 - 31/10/2018
Innovate UK/EPSRC €496,000 (€193k to Hull) (Greenman, Green, Cawthorne). Development of a multi-purpose small animal phantom for pre-clinical radiotherapy studies. 01/03/2016 - 28/02/2018.
Yorkshire Cancer Research €123,312 (Archibald, Madden & Greenman). Chemokine receptor targeted therapies. 01/02/2014 - 31/01/2016.
British Lung Foundation €24,800 (Loveday, Lind, Haswell & Greenman). Development of microfluidic device for response to chemotherapy in malignant mesothelioma. 01/10/2013 - 30/09/2015.
Technology Strategy Board Sepsis I: Multi-pathogen detection and/or simple discrimination €399,000 (Greenman, Dyer, Haswell, BioGene Ltd). Rapid, on-chip, multiplexed detection of sepsis-causing organisms from blood samples. 01/09/2012 - 31/08/2015.
FP7-SME-2012. Point-of-care blood device for fast and reliable prediction of drug response in non-small cell lung carcinoma patients from blood samples (LungCARD 315586) University of Hull (Haswell & Greenman); Hull and East Riding NHS Trust (Lind & Greenman) (€306,000 to Hull; 1.2M Euro total) 01/01/2013 - 28/2/2014.
NC3R €450,000 (Greenman, Madden, Flynn, Haswell, Maraveyas). Replacement of animal models for tumour biology with a multifunctional microfluidic-based approach. 01/10/2011 - 30/09/2014.
NIHR (i4i programme). €667,542 (Elliott, Wadhawan, Singh, MacFie, Greenman). Development of a placement sensing nasogastric tube. 01/07/2011 - 30/06/2014.
Hull and East Riding Cardiac Trust. €76,128 (Greenman, Jones, Dyer, Wadhawan, Haswell, Griffin, Seymour) Integrated microfluidic devices for real-time measurement of biochemical changes in heart tissue. 01/03/2011 - 30/11/2012.
Heart Research UK €199,728 (Greenman, Haswell and Seymour). Development of microfluidic devices for analysis of function in normal and diseased cardiac tissue. 10/2007 - 09/2011.
EPSRC EP/H007385 €210,949 (Haswell & Greenman). Commercialisation of lab-on-a-chip technology for DNA profiling. 08/2009 - 07/2010.
I welcome applications to work with me in either the biomedical applications of microfluidic devices or head and neck immunobiology. These can come from basic scientists or medically trained individuals.
90 postgraduate (PhD, MD and MSc (Research)) students successfully supervised since 1999.
Cheah, R. (2016), Monitoring the Response of Head and Neck Tumour Tissue to Irradiation Using a Microfluidic-Based Approach
Smith, J. (2016), The Effect of HNSCC-derived Soluble Factors on the Proliferation and Function of Immune Cells
Chandrabalan, K. (2016), A Microfluidic Approach to the Study of Cellular Responses to Oxidative Stress
Williamson, J. (2016), The Role of Endothelial Adhesins in Leukocyte Adhesion in Response to Pharmaceutical Agents that Induce Pulmonary Fibrosis
Todd, A. (2016), Role of Hypoxia-Induced Adam 10 in Colorectal Cancer Progression
Pacelli, A. (2015), Development of a Pet Probe for the Imaging of Cox-2 Expression in Cancers
Patel, R. (2016), An Observational Pilot Study to Assess the Potential of a Microfluidic Tissue Culture Model to Predict Rectal Cancer Response to Neo-Adjuvant Therapy
Zahoor, T. (2016), Does HPV-16 Seropositivity Correlate with T-cell Distribution Providing Additional Prognostic Information in Infected HNSCC Patients?
Carr, S. (2013), Assessing the Effects of Radiotherapy on Head and Neck Squamous Cell Carcinoma using Microfluidic Techniques
Current PhD supervisors
Currently acting as primary and secondary supervisor to 6 postgraduate students covering all aspects of my research interests.